English (United States)


reduce font Size enlarge font Size print content

EU-SolidAct - a pan-European platform for pandemic research and preparedness

There is an urgent need for rapid and coordinated investigation of new candidate drugs during pandemics.

EU-SolidAct is a new Adaptive Platform Trial developed to evaluate drug interventions in hospitalized patients with Covid-19 and to facilitate a joint European response to future pandemics.

The first patients were recruited in June with the opening of the control and Baricitinib arms.


Who should register?

Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.

Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.